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Introduction {#sec1}
============

The nucleotide-binding oligomerization domain-containing proteins NOD1 and NOD2 are cytosolic Nod-like receptor (NLR) family proteins that function in the innate immune system to detect pathogenic bacteria ([@bib40]). NOD1 is activated upon binding to bacterial peptidoglycan fragments containing diaminopimelic acid (DAP), whereas NOD2 recognizes muramyl dipeptide (MDP) constituents ([@bib6; @bib16; @bib17; @bib24]). NOD activation induces pro-inflammatory signaling by receptor-interacting protein kinase 2 (RIPK2, also known as RIP2 or RICK), which plays an obligatory and specific role in activation of NOD-dependent, but not Toll-like receptor responses ([@bib39]).

Signaling by RIPK2 is dependent on an N-terminal kinase domain with dual Ser/Thr and Tyr kinase activities ([@bib13; @bib46]), as well as a C-terminal caspase activation and recruitment domain (CARD) that mediates CARD-CARD domain assembly with activated NODs ([@bib23; @bib38]). Once engaged, RIPK2 is activated by autophosphorylation ([@bib13]) and further targeted by XIAP (X-linked inhibitor of apoptosis) and other E3 ligases for non-degradative polyubiquitination ([@bib4; @bib11; @bib45; @bib47; @bib52; @bib53]). The ubiquitin-conjugated protein subsequently activates the TAK1 and IKK kinases, leading to upregulation of both the mitogen-activated protein kinase and nuclear factor κB (NF-κB) signaling pathways ([@bib27; @bib39]). In addition, RIPK2 induces an antibacterial autophagic response by signaling between NODs and the autophagy factor ATG16L1 ([@bib7; @bib20]).

The NOD2-RIPK2 pathway has attracted special interest due to the role of this signaling node in granulomatous inflammatory diseases, including inflammatory bowel disease (IBD). Such pathologies can arise from either positive or negative dysregulation of the pathway ([@bib5; @bib25; @bib40]). Genetic variants in *NOD2* are the strongest susceptibility factor to Crohn\'s disease ([@bib22; @bib25; @bib37]). Crohn\'s disease-associated mutations that abrogate NOD2 binding to MDP may induce excessive inflammatory signaling from other pattern recognition receptors, including NOD1 ([@bib9; @bib24]). In contrast, mutations in the second major Crohn\'s disease susceptibility factor, ATG16L1, disrupt an inhibitory interaction with NOD2 and consequently increase the activation of RIPK2 ([@bib44]). Excessive RIPK2 activation has also been reported in pediatric Crohn\'s disease ([@bib34]). In addition, gain of function in the NOD2-RIPK2 pathway has been linked to Blau syndrome, early-onset sarcoidosis, allergic airway inflammation, and multiple sclerosis ([@bib18; @bib26; @bib43]). Overall, these data establish RIPK2 as a key molecule for the understanding of IBD pathogenesis as well as a potential therapeutic target in a wide spectrum of inflammatory and autoimmune diseases.

Importantly, the kinase activity of RIPK2 is essential for its stability and function, offering a promising rationale for small-molecule intervention ([@bib35; @bib46]). To date, all studies of RIPK2 have focused on small molecules of the type I inhibitor class, which bind to the kinase ATP pocket and are ATP competitive. This approach was first validated using SB203580, a pyridinyl imidazole inhibitor of p38, which showed additional inhibition of RIPK2 in vitro and was efficacious in a Crohn\'s disease model in mice ([@bib3; @bib19]). Further proof of concept was subsequently attained using the clinical epidermal growth factor receptor inhibitor, gefitinib, which also inhibited RIPK2 and improved disease burden in a spontaneous model of Crohn\'s disease-like ileitis ([@bib46; @bib48]). Finally, a new class of macrocyclic RIPK2 inhibitors has recently been described as capable of inhibiting cellular NOD-dependent inflammatory responses at 200--500 nM ([@bib48]). These molecules also displayed promising in vivo activity in models of Crohn\'s ileitis as well as NOD-driven peritonitis ([@bib48]).

Here, we show that the inhibition of RIPK2 signaling can be improved by two orders of magnitude by using type II inhibitors that alternatively target the inactive "DFG-out" conformation of the kinase domain, including the US Food and Drug Administration (FDA)-approved drugs ponatinib, sorafenib, and regorafenib. Type II binding is confirmed by the first crystal structure of RIPK2 solved in complex with ponatinib, which reveals an allosteric site suitable for the rational design of RIPK2-selective small molecules. The identified clinical inhibitors disrupt RIPK2 activation in monocytes and macrophages to selectively reduce inflammatory signaling from NOD1 and NOD2, but not tumor necrosis factor (TNF) induction from Toll-like receptors. Overall, this work identifies the structural basis to investigate the therapeutic potential of RIPK2 inhibition in inflammatory diseases by defining clinically relevant scaffolds for the development of selective RIPK2 inhibitors.

Results {#sec2}
=======

Identification of Ponatinib as a Potent Inhibitor of RIPK2 {#sec2.1}
----------------------------------------------------------

To identify inhibitors of human RIPK2, we purified the recombinant kinase domain from Sf9 insect cells and screened it against a library of small-molecule kinase inhibitors using a fluorescence-based thermal shift assay ([@bib36]). In this assay, the previously reported type I inhibitors gefitinib and LDN-193189 yielded large thermal shift (Δ*T*~m~) values of 9.5°C and 12.1°C, consistent with their respective IC~50~ values of 49 nM ([@bib48]) and 25 nM ([@bib49]). By comparison, the type II inhibitor ponatinib yielded a remarkable Δ*T*~m~ of 23.1°C and was identified as the most potent hit ([Table S1](#mmc1){ref-type="supplementary-material"}). To further explore type II inhibitors as putative preferred scaffolds for RIPK2, we set out to solve the co-crystal structure of RIPK2 with ponatinib. Protein crystallization was hindered initially by heterogeneous phosphorylation, but was enabled following treatment with lambda phosphatase. Viable crystals were grown in space group *P*2~1~2~1~2~1~ with two molecules in the asymmetric unit. The structure was solved by molecular replacement and refined at 2.75 Å resolution. Crystallographic data collection and refinement statistics are presented in [Table S2](#mmc1){ref-type="supplementary-material"}.

Structural Features of RIPK2 {#sec2.2}
----------------------------

The structure of RIPK2 exhibits the canonical bilobal kinase fold followed by a 16-residue αJ helix that packs alongside the loop connecting the αD and αE helices ([Figure 1](#fig1){ref-type="fig"}A). This C-terminal structural element is common in STE family kinases, but is present additionally in RIPK1-3 ([Figure 1](#fig1){ref-type="fig"}B). The bound ponatinib inhibitor occupies the ATP pocket established between the N- and C-terminal lobes of the kinase. As a result, RIPK2 displays an inactive conformation of the catalytic domain characterized by a "DFG-Asp out, αC-Glu in" configuration. The β3 lysine (Lys47) and αC glutamine (Glu66) establish the catalytically relevant salt bridge, whereas the DFG aspartate (Asp164) is flipped away from the active site, rendering the enzyme inactive. Of note, the activation segment helix found in the crystal structures of the two homologous kinases, RIPK1 and RIPK3, is not present in RIPK2, although a significant portion of the activation loop was not visible in the electron density map and not modeled ([Figure 1](#fig1){ref-type="fig"}B). Residues from this helix, in particular Ser161, are known to contribute to the binding of RIPK1 to selective small-molecule inhibitors, necrostatins ([@bib50]). Interestingly, RIPK2 also contains several unusual sequence changes in its catalytic motifs that are not conserved in other RIPKs. The typical HRD triad in the catalytic loop is changed to HHD, while the activation loop APE motif is changed to PPE ([Figure 1](#fig1){ref-type="fig"}C). Moreover, the kinase domain of RIPK2 as a whole displays only 33% sequence identity with other proteins in the PDB (namely RIPK1 and RIPK3), indicating its broader diversity.

Oligomerization into multi-protein signaling complexes is a key part of the activation mechanism in the RIPK family. The RIPK2 structure reveals a homodimeric packing arrangement similar to that of RIPK3 ([@bib51]) and consistent with the dimeric state observed in solution by analytical gel filtration ([Figure S1](#mmc1){ref-type="supplementary-material"}). The protein interface is highly symmetrical, with the two active sites facing in opposite directions and rotated approximately 90° relative to one another ([Figure 2](#fig2){ref-type="fig"}). Binding is supported by the αJ helices, which pack against each other in an antiparallel fashion, and form both hydrophobic interactions and a symmetrical pattern of hydrogen bonding between the side chains of Lys310 and Glu299 and the side chains of His159 and Glu157 ([Figure 2](#fig2){ref-type="fig"}). Additional contacts are made between the β2-β3 loop of one subunit and the αE and αI helices of the other ([Figure 2](#fig2){ref-type="fig"}).

The Binding Mode of Ponatinib and Other Clinically Relevant Type II Inhibitors {#sec2.3}
------------------------------------------------------------------------------

Ponatinib ([Figure 3](#fig3){ref-type="fig"}A) has been crystallized previously only in complex with tyrosine kinases. The binding mode in RIPK2 resembles that of DDR1 and KIT with an intact conformation of the β1-β2 hairpin, rather than the collapsed loop of Abl ([Figure 3](#fig3){ref-type="fig"}B). The imidazo\[1,2-*b*\]pyridazine head group establishes a single hydrogen bond to the hinge residue Met98 as well as hydrophobic interactions with Tyr97 and Leu24. The central linker forms two additional hydrogen bonds with the side chain of Glu66 and the main-chain nitrogen of Asp164. The trifluoromethyl group occupies the hydrophobic pocket vacated by the inverted DFG motif, while the protonated methylpiperazine forms an ionic-dipole interaction with the main-chain oxygen atoms of Leu143 and His144, positioned within the αD-β6 loop ([Figure 3](#fig3){ref-type="fig"}B). Importantly, the structure also reveals opportunities for the development of RIPK2-selective molecules. In particular, the allosteric hydrophobic pocket occupied by the trifluoromethyl group is greatly enlarged in RIPK2 due to the presence of Ala73 in the αC helix ([Figure 3](#fig3){ref-type="fig"}C). Nearly all kinases contain a bulky side chain at this position, such as Leu70 in RIPK1. Thus, larger chemical groups at this site will not only increase potency for RIPK2, but will also sterically restrict inhibitor binding to the wider kinome.

Regorafenib and sorafenib are two other multi-targeted clinical type II inhibitors that share a phenyl-urea-trifluoromethylphenyl core ([Figure 3](#fig3){ref-type="fig"}A). Docking studies suggested that these molecules can assume a binding pose similar to that of ponatinib in RIPK2, including a total of five hydrogen bonds formed with Met98, Glu66, and Asp164 ([Figures 3](#fig3){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}). To test these predictions, we performed in vitro kinase assays using the ADP-Glo assay. Ponatinib inhibited the activity of recombinant RIPK2 with an IC~50~ value of 6.7 nM, demonstrating inhibition comparable with that of Abl (IC~50~ = 1.6 nM, [Figure 3](#fig3){ref-type="fig"}E). By comparison, the inhibition of RIPK2 by regorafenib and sorafenib was an order of magnitude weaker (IC~50~ values of 41 and 75 nM, respectively), but similar to the activity of the previously reported type I inhibitor gefitinib (IC~50~ = 51 nM, [Figure 3](#fig3){ref-type="fig"}F). This likely reflects the loss of the ionic-dipole interactions formed by the distal piperazine of ponatinib with the main-chain oxygen atoms of Leu143 and His144. Consistently, changes to this moiety, which is present in ponatinib but not sorafenib or regorafenib, were reported to partially attenuate inhibition of Abl kinase ([@bib21]).

Inhibition of Cellular RIPK2 Activation {#sec2.4}
---------------------------------------

The kinase activity of RIPK2 has been shown to mediate the activation of inflammatory signaling by the NOD1/2 family of peptidoglycan receptors. Autophosphorylation of Ser176 in the kinase activation segment has been identified as a specific marker of RIPK2 activation ([@bib13; @bib32]). To confirm inhibition of cellular RIPK2 activation by the inhibitors, we therefore analyzed changes in phospho-Ser176-RIPK2 (p-RIPK2) following stimulation of NOD2-expressing HEK293 cells with L18-MDP ligand (a lipidated form of MDP with enhanced potency). L18-MDP caused a rapid increase in endogenous p-RIPK2 that was inhibited by low nanomolar concentrations of ponatinib, sorafenib, and regorafenib ([Figure 4](#fig4){ref-type="fig"}A). Ponatinib displayed the highest activity, completely blocking RIPK2 phosphorylation at 10 nM, followed by regorafenib and sorafenib. This was consistent with the order of activities observed in the in vitro kinase assays. Furthermore, by blocking RIPK2 activation the inhibitors prevented the phosphorylation and subsequent degradation of IκBα ([Figures 4](#fig4){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}), which is required for activation of NF-κB and induction of inflammatory gene expression ([@bib10]). Surprisingly, the type I inhibitor gefitinib showed much lower activity in cells relative to the in vitro assays ([Figure 4](#fig4){ref-type="fig"}A). This may partly reflect its ATP-competitive mode of action, with potential loss of activity due to the high concentrations of ATP in cells. None of the molecules significantly inhibited phosphorylation of ERK1/2 or global levels of phosphotyrosine proteins, which served as negative controls ([Figure 4](#fig4){ref-type="fig"}A). In addition, none of the inhibitors affected the viability or morphological appearance of HEKBlue or RAW264.7 macrophage cells, except for 100 nM ponatinib, which caused rounding of RAW cells and likely reflects off-target activity at the highest concentration ([Figure S4](#mmc1){ref-type="supplementary-material"}).

To further quantify cellular RIPK2 inhibition, we measured the downstream activation of NF-κB in the same HEKBlue cells, which were also stably transfected with an NF-κB-SEAP reporter. Ponatinib again displayed the most potent, low nanomolar activity (EC~50~ = 0.8 nM), followed by regorafenib and sorafenib ([Figure 4](#fig4){ref-type="fig"}B). By comparison, gefitinib inhibited NF-κB activity with an EC~50~ value of 7.8 μM, consistent with the p-RIPK2 data. Overall, these data identified ponatinib, sorafenib, and regorafenib as a new class of low nanomolar inhibitors of RIPK2 activation in cells.

Since ponatinib is a potent inhibitor of Abl, we further examined whether Abl may contribute to the inhibition of the NOD2 responses in HEK cells in addition to RIPK2. We found that a different type II inhibitor of Abl, nilotinib, did not inhibit either RIPK2 in vitro ([Figure S5](#mmc1){ref-type="supplementary-material"}A) or the NOD2 response in HEKBlue cells ([Figure S5](#mmc1){ref-type="supplementary-material"}B). Because ponatinib is a large lipophilic molecule, which may cause non-specific effects, we also sought to identify close analogs that would lack activity against RIPK2. We noticed that methyl of the central phenyl ring of ponatinib inserts into the shallow lipophilic pocket formed by aliphatic side chains of Val32, Lys47, Ile93, and Thr95. A bulkier *tert*-butyl side chain (CS6, [Figure 3](#fig3){ref-type="fig"}A) was designed based on this hypothesis and synthesized using previously reported methods ([@bib21; @bib33]). Introduction of the *tert*-butyl led to the loss of inhibition of both RIPK2 and Abl kinase activity ([Figure S5](#mmc1){ref-type="supplementary-material"}A), providing us with a bulky and lipophilic control molecule. Importantly, CS6 did not inhibit the MDP response in HEKBlue cells ([Figure S5](#mmc1){ref-type="supplementary-material"}B). These data and the lack of cellular activity of nilotinib further confirmed the specific role of RIPK2 inhibition in these assays.

To explore the mechanism of RIPK2 inhibition, we tested the effects of ponatinib on the required interaction with NOD2. For this, we used U2OS cells that inducibly expressed HA-tagged NOD2 and performed HA-immunoprecipitation to recover bound RIPK2. As expected, HA-NOD2 expression was detected only in the presence of doxycycline, and induced a robust interaction with RIPK2 ([Figure 4](#fig4){ref-type="fig"}C) as well as downstream NF-κB activation ([Figure 4](#fig4){ref-type="fig"}D). Interestingly, the NOD2-RIPK2 interaction was stably maintained in the presence of 100 nM ponatinib ([Figure 4](#fig4){ref-type="fig"}C), whereas NF-κB activation was completely disabled ([Figure 4](#fig4){ref-type="fig"}D). These results indicated that ponatinib acts to inhibit the activation of the kinase domain of RIPK2 but does not interfere with the C-terminal CARD domain, which recognizes NOD2.

Ponatinib Potently Abrogates RIPK2 Ubiquitination and Induction of Inflammatory Cytokines {#sec2.5}
-----------------------------------------------------------------------------------------

To examine inhibition of RIPK2-induced inflammation in a more physiological context, we analyzed the receptor signaling pathway in human monocytic THP-1 cells and in mouse macrophage RAW264.7 cells in response to different PRR (pattern recognition receptor) ligands and cytokines. Stimulation of NOD2 by MDP leads to rapid ubiquitination of RIPK2 by XIAP and other ubiquitin ligases, a process required for downstream signaling and transcription of NF-κB target genes ([@bib11; @bib12; @bib15; @bib53]). Consistent with the relative potency of the kinase inhibitors against RIPK2 activity, pre-treatment of THP-1 cells with 100 nM ponatinib completely blocked L18-MDP-induced RIPK2 ubiquitination, whereas regorafenib and gefitinib at the same concentration had less robust inhibitory effects ([Figures 5](#fig5){ref-type="fig"}A and [S6](#mmc1){ref-type="supplementary-material"}). Ponatinib also blocked the downstream degradation of IκBα, whereas the other inhibitors had little or no detectable effect ([Figure 5](#fig5){ref-type="fig"}A). Importantly, ponatinib interfered with RIPK2 ubiquitination in a dose-dependent manner. Concentrations as low as 5--10 nM reduced the extent and length of ubiquitin-modified RIPK2, while RIPK2 ubiquitination was completely blocked at concentrations of 25 nM or higher ([Figure 5](#fig5){ref-type="fig"}B). By contrast, ponatinib had no obvious effects on ubiquitination of the related kinase RIPK1 or IκBα degradation following treatment of THP-1 cells with TNF ([Figure 5](#fig5){ref-type="fig"}C).

We next analyzed the pattern of inflammatory gene expression in RAW264.7 macrophage cells. Consistent with the results obtained in THP-1 cells, MDP stimulation led to robust increases in *CCL4*, *CXCL2*, and *RANTES* mRNA levels that were efficiently inhibited by low nanomolar (1--10 nM) concentrations of ponatinib ([Figure 6](#fig6){ref-type="fig"}A). Regorafenib was similarly active at 10--100 nM while sorafenib was slightly less effective ([Figure 6](#fig6){ref-type="fig"}A). Comparable results were observed following RIPK2 stimulation with the NOD1 agonist, Tri-DAP ([Figure 6](#fig6){ref-type="fig"}B). In contrast, ponatinib and the other inhibitors did not block the mRNA induction by a different class of PAMPs (pathogen-associated molecular patterns), such as agonists of Toll-like receptors 2 and 4 (Pam3CSK4 and lipopolysaccharide \[LPS\], respectively) ([Figures 6](#fig6){ref-type="fig"}C and 6D). The only exception was 100 nM ponatinib, which partially attenuated both the LPS and Pam3CSK4 responses, likely reflecting non-specific activity of this inhibitor at higher concentrations. Overall, we were able to observe selective and efficient inhibition of RIPK2-dependent NOD1/2 responses by both ponatinib and regorafenib at low nanomolar concentrations and by sorafenib at ≤100 nM.

Modulation of NOD1/2-RIPK2-XIAP-mediated signaling has been proposed as a therapeutic approach for inflammatory disorders ([@bib26]). Therefore, we investigated whether NOD2 receptor activation in primary human monocytes can be inhibited to an extent similar to that observed for the described epithelial and leukocyte cell lines. Ponatinib, regorafenib, and gefitinib inhibited the production of TNF in peripheral blood-derived monocytes after L18-MDP stimulation ([Figure 7](#fig7){ref-type="fig"}A). The most potent inhibition was observed with ponatinib, which completely abrogated NOD2-dependent TNF production at low nanomolar concentrations down to 10 nM ([Figure 7](#fig7){ref-type="fig"}B). Regorafenib was similarly effective at 100 nM, whereas a much higher concentration of gefitinib (10 μM) was required for complete inhibition ([Figure 7](#fig7){ref-type="fig"}B). TNF production by LPS stimulation was not affected at these inhibitor concentrations ([Figures 7](#fig7){ref-type="fig"}A and 7B), and was attenuated only by ponatinib at the much higher concentration of 1 μM ([Figure 7](#fig7){ref-type="fig"}B). Similar inhibitor efficacies were observed in the human monocytic cell line THP-1, although baseline response in these cells was low and 10 μM gefitinib also inhibited the LPS pathway ([Figure S7](#mmc1){ref-type="supplementary-material"}).

Overall, the results on primary human monocytes are fully consistent with the earlier data obtained in laboratory cell lines, suggesting that the tested cell lines provide an accurate tool to assess the potency of RIPK2 inhibition. Furthermore, they support the hypothesis that tyrosine kinase inhibitors can be used in primary human cells to selectively target RIPK2.

Discussion {#sec3}
==========

To date, all reported RIPK2 inhibitors have been ATP-competitive type I molecules, such as the clinical drug gefitinib. Importantly, we observed that the cellular activity of this type I inhibitor was vastly outperformed by the identified type II inhibitors, despite their comparable potencies in the in vitro kinase assay (e.g., comparing regorafenib and gefitinib). Multiple factors could contribute to these differences. For example, the endogenous full-length RIPK2 may display a higher affinity for ATP than the isolated kinase domain, resulting in greater competition for type I binders. Alternatively, the DFG-out conformation might represent a preferred conformation in cells, or perhaps form a dominant-negative species. Indeed, activation loop phosphorylation in JAK2 is incompatible with the binding of type II inhibitors, but permissible with inhibitors of the type I class ([@bib2]). While the mechanistic basis for these differences remains to be further elucidated, these data clearly identify type II inhibitors as the most efficacious molecular class for targeting RIPK2.

The potency of the type II inhibitors also affords new tools with which to investigate the molecular mechanisms of RIPK2 signaling and the effects of kinase inhibition. We found that ponatinib blocked the activation of the kinase domain of RIPK2 without affecting the C-terminal CARD domain and its engagement of NOD2. A similar breakdown in RIPK2 activation has been reported for a NOD1 variant containing the rare Asn43Ser polymorphism ([@bib29]). However, in the absence of structural information there is little understanding of how the CARD domain status of RIPK2 is communicated to the kinase domain. Potentially, new stimulatory interactions could be formed or inhibitory interactions broken. All the tested inhibitors were able to block the phosphorylation of the kinase activation loop (Ser176), which is a known marker for RIPK2 activation. Activated RIPK2 is also targeted by multiple E3 ligases for polyubiquitination by mechanisms that are yet to be structurally characterized. Unexpectedly, we found that ponatinib could inhibit this modification completely, whereas type I inhibitors have previously only caused a delay in ubiquitination ([@bib32]). This result suggests that RIPK2 binding to E3 ligases is more strictly regulated than previously imagined. Thus, it will be interesting to decipher the precise mechanism of E3 recruitment in future work. We also observed excellent selectivity of the inhibitors toward MDP-dependent signaling relative to LPS-dependent pathways. This result is noteworthy given the known promiscuity of ponatinib within the kinome ([@bib54]). It also further supports the specificity of RIPK2 for NOD-dependent signaling ([@bib39]).

In a separate study, we have found that ponatinib is also an efficient inhibitor of RIPK1 and RIPK3 kinase activity in necroptosis ([@bib33]), making this molecule the only known pan-RIPK inhibitor. The current work using ponatinib and TNF stimulation, in line with previous reports, shows that RIPK1 kinase activity is dispensable for its ubiquitination as well as for the downstream degradation of IκBα ([@bib28]). Thus, the experiments with ponatinib reveal important differences in the mechanisms of RIPK1 and RIPK2. Nonetheless, the ability of ponatinib to simultaneously target multiple RIPKs may be of interest for investigating inflammatory disorders. By contrast, inhibition of RIPK1/RIPK3 was not observed with sorafenib or regorafenib (data not shown). These two inhibitors lack the methylpiperazine group that is present in ponatinib. The activation segments in RIPK1/RIPK3 also show a high propensity to form a short α helix that is not observed in the RIPK2 structure. Additional co-structures and SAR may be required to understand the selectivity differences that must exist between the DFG-out (DLG in RIPK1) pockets of these kinases.

Importantly, ponatinib, regorafenib, and sorafenib are FDA-approved medications that are used clinically against various forms of cancer. Inhibition of RIPK2 represents a novel off-target activity, although microbiota-driven inflammation has emerged as a potentially important player in tumorigenesis ([@bib14; @bib41]). IBD is also a known risk factor for colorectal cancer ([@bib42]). Nonetheless, the broad kinase selectivity of these drugs currently prohibits their use in chronic inflammatory conditions. In particular, ponatinib can cause serious adverse events including vascular thrombosis ([@bib8]). Sorafenib and regorafenib are better tolerated and are used clinically at low-micromolar doses that are higher than those used in our study ([@bib30; @bib31]). These molecules are therefore potentially interesting tools with which to further explore RIPK2 function in pre-clinical models of colitis and other inflammatory conditions.

Finally, this work also suggests that more selective compounds may be derived by targeting the expanded allosteric pocket identified in the RIPK2 structure. For example, the trifluoromethyl group could be replaced with a larger substitute, such as methoxymethyl, isopropyl, or isopropoxy. All of these groups have the potential to extend further into the RIPK2 pocket without dramatic changes in hydrogen bonding or lipophilicity. In addition, changes to the hinge-binding "head" group could be considered by comparison with RIPK2-selective type I inhibitors such as WEHI-345 ([@bib32]). The recently identified macrocycles OD36 and OD38 would, however, form steric clashes in a type II binding mode ([@bib48]). The toolbox of new compounds will form valuable reagents for further investigation of the complexity of RIPK2 regulation in both normal signaling and pathobiology.

Significance {#sec4}
============

**Clinical kinase inhibitors have been utilized almost exclusively in oncology. The recent approval of JAK inhibitors for the treatment of inflammatory conditions, in particular rheumatoid arthritis, has demonstrated the potential of this drug class to target other indications. RIPK2 is one emerging therapeutic target in inflammation strongly supported by genetic evidence of activating NOD2 mutations in the monogenic autoinflammatory disease Blau syndrome, characterized by early-onset granulomatous arthritis, uveitis, and dermatitis. To date, pre-clinical validation studies for inflammatory conditions have largely focused on the clinical inhibitor gefitinib, which binds to kinases in their active conformation. Here, we show that RIPK2 is highly amenable to type II inhibition, which affords dramatic improvements in cellular potency. Furthermore, the most potent molecules, ponatinib, regorafenib, and sorafenib, extend the available inhibitor activities from micromolar to subnanomolar, allowing fine-tuning insights into RIPK2 regulation. In particular, binding of ponatinib to the kinase domain is sufficient to block all ubiquitination on RIPK2, and demonstrates the requirement for this modification for the downstream destruction of IκBα, in contrast to the requirements of RIPK1. In addition, regorafenib offers selectivity for RIPK2 over RIPK1/3 as well as low nanomolar potency to alleviate some "off-target" effects. Further scaffold improvements to overcome such liabilities are also suggested by the presented RIPK2 structure. Overall, this work identifies advanced tools to investigate the functional role of RIPK2 in control of the intestinal microbiota as well as clinically relevant scaffolds to explore the therapeutic potential of RIPK2 inhibition in inflammatory diseases.**

Experimental Procedures {#sec5}
=======================

Cells and Reagents {#sec5.1}
------------------

Detailed information on reagents, qPCR, and immunoblotting is provided in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Purification of RIPK2 {#sec5.2}
---------------------

Human RIPK2 (Uniprot: [O43353](uniprotkb:O43353){#intref0010}, residues 8--317) was expressed in Sf9 insect cells, and purified by nickel affinity and size-exclusion chromatography. Detailed information is provided in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Crystallization and Structure Determination {#sec5.3}
-------------------------------------------

RIPK2 was concentrated to 3.7 mg/ml. Crystals with ponatinib were grown in sitting drops using a reservoir solution containing 0.1 M ammonium citrate and 16% (w/v) polyethylene glycol 3350. Diffraction data were collected on Diamond Light Source beamline I04. Detailed information on structure determination is provided in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Thermal Shift Assay {#sec5.4}
-------------------

RIPK2 protein at 2 μM concentration was mixed with inhibitor compounds at 10 μM and a 1:1,000 dilution of SyproOrange fluorescent dye (Invitrogen). Fluorescence-based thermal shift assays were performed in an Mx3005p real-time PCR machine (Agilent) as described by [@bib36].

ADPGlo In Vitro Kinase Assays {#sec5.5}
-----------------------------

For ADPGlo (Promega) assays, 1 ng of Abl or 10 ng of RIPK2 was diluted in reaction buffer (40 mM Tris-HCl \[pH 7.5\], 20 mM MgCl~2~, 0.5 mM DTT, and 0.01% BSA) supplemented with 50 μM ATP and a 10-point dose range of inhibitors. Detailed information is provided in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

HEKBlue Activation Assay {#sec5.6}
------------------------

HEKBlue cells (1 × 10^5^ cells/ml) were resuspended in QUIATI-Blue detection medium and seeded into 96-well plates (100 μl/well). Cells were treated with small-molecule inhibitors and 1 μg/ml L18-MDP for 8--10 hr. Absorbance at 620 nM was determined at the end of the incubation using a Victor3V plate reader (PerkinElmer). Values of empty media were subtracted from all experimental samples. Resulting specific signal values were used to calculate inhibition: % = (1 − \[control (DMSO, L18-MDP) − sample (compound, L18-MDP)\]/\[control (DMSO, L18-MDP) − control (DMSO)\]) × 100. EC~50~ values were determined using non-linear regression in the Prism software package (GraphPad).

Purification of Ubiquitin Conjugates {#sec5.7}
------------------------------------

The ubiquitin conjugates were purified using GST-Tandem Ubiquitin Binding Entities (TUBE; [@bib15]). In brief, treated THP-1 cells (6--10 × 10^6^) were washed with PBS and lysed in 400 μl of ice-cold lysis buffer containing TUBE on ice for 30 min. Cleared lysates were incubated with Glutathione Sepharose 4B resin (Amersham) with agitation at 4°C overnight. The beads were washed four times with PBS-Tween (0.1%) and the bound proteins were released by heating the beads in reducing SDS sample buffer. The samples were resolved on pre-cast gradient gels (NuPage; Life Technologies) in MOPS running buffer and subjected to immunoblotting.

Flow Cytometry Analysis {#sec5.8}
-----------------------

Human blood primary immune cells were obtained from healthy donors. Ethical approval was obtained from the Oxfordshire Research Ethics Committee (Reference 09/H0606/5), and informed written consent was given by all donors. L18-MDP stimulation assay was performed as previously described ([@bib1]). In brief, healthy donor peripheral blood mononuclear cells (PBMC) were isolated by gradient centrifugation and cultured in RPMI1640 supplemented with 10% fetal calf serum. To enrich for monocytes, PBMC (2.5 × 10^6^ cells) were plated in six-well plates and rested overnight. The following day, cells were gently washed with PBS and pre-incubated for 60 min with indicated concentrations of inhibitors followed by receptor activation with 200 ng/ml L18-MDP (InvivoGen) or 200 ng/ml LPS (Enzo Life Sciences) in the presence of Golgiplug (BD Biosciences). After 2.5 hr of stimulation, cells were harvested by scraping, put on ice, and stained with fixable viability dye (eBioscience) and surface monocyte markers. Following fixation and cell permeabilization (Cytofix/Cytoperm Kit; BD Biosciences) cells were stained for intracellular production of TNF. The following antibodies were used: anti-TNF-α (clone MAb11; eBioscience), anti-CD14 (clone M5E2; BioLegend), and anti-HLA-DR (clone L243; BioLegend). Results were acquired by flow cytometry (LSRFortessa; BD Biosciences) and data were analyzed using FlowJo software (version 10.0.6; Treestar).
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![Structural Features of the RIPK2 Kinase Domain\
(A) Crystal structure of the kinase domain of human RIPK2 showing the bound ponatinib molecule. See also [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.\
(B) Superposition of the kinase domains of RIPK1 (pink, PDB: [4NEU](pdb:4NEU){#intref0020}), RIPK2 (white), and RIPK3 (blue, PDB: [4M69](pdb:4M69){#intref0025}). The activation segment helix present in the structures of RIPK1 and RIPK3 is marked.\
(C) Sequence alignment of the kinase domains of human RIPK1--3. Residue numbers refer to the RIPK2 sequence, and secondary structure elements labeled in (A) are marked.](gr1){#fig1}

![The RIPK2 Kinase Domain Is Dimeric\
The main panel shows the overall arrangement of the two monomers, and the inset panels show selected residues in the dimer interface. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Inhibition of Abl and RIPK2 Kinases In Vitro\
(A) Chemical structures of inhibitors used in this study.\
(B) Binding mode of ponatinib to RIPK2.\
(C) The DFG-out hydrophobic pocket in RIPK2 is almost uniquely large due to the small Ala73, which replaces the Ile/Leu residues of Abl/DDR2. A dashed line highlights the expanded pocket area in RIPK2, which may accommodate larger substitutions of the trifluoromethyl group for improved selectivity.\
(D) Predicted binding mode of regorafenib. Docking was performed with ICM-Pro (Molsoft). See also [Figure S2](#mmc1){ref-type="supplementary-material"}.\
(E) Dose-response curves showing ponatinib inhibition of RIPK2 and Abl.\
(F) Dose-response curves for RIPK2 inhibition by sorefanib, regorafenib, and gefitinib. In (E) and (F), experiments were performed in duplicate; error bars indicate SD values. Kinase activity was measured using the ADPGlo assay. Non-linear curve fitting to calculate IC~50~ values was performed using Prism software. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Inhibition of RIPK2 Activation in HEKBlue and U2OS Cells\
(A) Phosphorylation changes in HEKBlue cells. Cells were treated with indicated concentrations of inhibitors, followed 30 min later by stimulation with 1 μg/ml L18-MDP. Cells were harvested after 30 min, and changes in protein phosphorylation were analyzed by western blotting. Levels of tubulin and total RIPK2 were used as loading controls.\
(B) Inhibition of NF-κB activation in HEKBlue cells. HEKBlue reporter cells, expressing NOD2 and NF-κB-SEAP reporter, were treated with 6--8 concentrations of each inhibitor in triplicate followed by stimulation with 1 μg/ml L18-MDP for 8 hr. SEAP activity was detected using HEKBlue media with detection of absorbance at 620 nM in a Wallac3V plate reader. Non-linear curve fitting to calculate EC~50~ values was performed using Prism software. Experiments were performed in triplicate, error bars indicate SD values. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.\
(C) Interaction of RIPK2 with inducibly overexpressed HA-NOD2 in U2OS cells in the presence of ponatinib. The immunoprecipitation was performed using anti-HA agarose after 24 hr of HA-NOD2 induction and ponatinib treatment. Dox, doxycycline. Representative result of the experiment performed three times.\
(D) NF-κB dual luciferase reporter assay in U2OS cells inducibly overexpressing HA-NOD2 and treated with ponatinib for 24 hr. Dox, doxycycline. Experiment performed three times in three technical replicates. Error bars represent ±SEM. ^∗∗∗∗^p \< 0.0001.](gr4){#fig4}

![Inhibition of NOD2-Dependent Ubiquitination and Signaling\
(A--C) THP-1 cells were pre-treated with kinase inhibitors or DMSO for 30 min and stimulated with 200 ng/ml L18-MDP (A, B) or TNF (C) as indicated. At the indicated time points, cells were lysed and ubiquitinated proteins were isolated using TUBE reagent. The isolated ubiquitinated proteins and input material were analyzed by immunoblotting. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![Inhibition of NOD-Dependent Inflammatory Gene Expression in RAW264.7 Cells\
(A and B) Cells were pre-treated with 1, 10, or 100 nM inhibitors for 30 min and stimulated with 10 μg/ml MDP (A) or Tri-DAP (B) for 18--24 hr in triplicate. RNA samples were isolated and changes in gene expression were analyzed using gene-specific primers using SYBR qRT-PCR. All values were normalized to the levels of *GAPDH*.\
(C and D) Lack of inhibition of Toll-like receptor-dependent inflammatory gene expression in RAW264.7 cells. Experiments were performed as described above, except cells were stimulated with 10 ng/ml *E. coli* LPS (C) or 500 ng/ml Pam3CSK4 (D).\
All experiments were performed in triplicate; error bars indicate SD values.](gr6){#fig6}

![Dose-Dependent Inhibitory Effect of Ponatinib, Regorafenib, and Gefitinib on MDP-Induced TNF in Primary Human Monocytes\
Intracellular TNF production was determined by flow cytometry in rested monocytes of healthy blood donors cultured in the presence or absence of L18-MDP (200 ng/ml) or LPS (200 ng/ml). Cells were pre-treated with the indicated concentrations of inhibitors for 60 min before receptor activation.\
(A) Representative fluorescence-activated cell sorting density blots of TNF-positive monocytes among all single, live, HLA-DR^+^, and CD14^+^ cells.\
(B) Induction of TNF in monocytes after L18-MDP or LPS stimulation is calculated as ΔTNF, subtracting the frequency of TNF-producing monocytes cultured in medium alone from the percentage of TNF-positive monocytes following activation. Experimental conditions are measured in 4--5 healthy donors. Individual replicates and the mean connected by a line are shown. Gray background indicates range without inhibitors.\
See also [Figure S7](#mmc1){ref-type="supplementary-material"}.](gr7){#fig7}
